Freestone Grove Partners LP Halozyme Therapeutics, Inc. Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 6,839 shares of HALO stock, worth $395,089. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,839Holding current value
$395,089% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
546Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.02 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$767 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$415 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$241 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$199 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.05B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...